Mark Baldry - Nov 3, 2022 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Chief Commercial Officer
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Stock symbol
XFOR
Transactions as of
Nov 3, 2022
Transactions value $
$644,490
Form type
4
Date filed
11/4/2022, 04:18 PM
Next filing
Nov 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XFOR Stock Option (right to buy) Award $644K +341K $1.89 341K Nov 3, 2022 Common Stock 341K $1.89 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on November 3, 2023, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.